When will CMS announce the addition of GLP-1 drugs for obesity to Part D?

The key fact is that CMS has already taken a meaningful step by launching a temporary Medicare bridge for GLP-1 obesity drugs, which shows policy momentum and administrative willingness to address access. But the bridge is explicitly a demonstration outside the standard Part D structure, and the available context still points to the long-standing rule that drugs used solely for weight loss are generally excluded from Part D unless CMS makes a broader policy change. That makes the event about a second, more consequential announcement, not just the bridge itself, and there is not yet strong evidence that CMS has crossed that threshold.

The strongest argument for a Yes outcome is that CMS is already actively managing this issue and may decide to formalize coverage as part of a 2027 guidance or rulemaking package, especially if the bridge is seen as a transition rather than an endpoint. Reports mentioning November guidance and the possibility of successor models suggest that the agency could use the end of 2026 to clarify the longer-term structure. In that sense, the odds are not negligible because the policy path is open and the political pressure for Medicare access to GLP-1s is substantial.

The strongest argument against Yes is that the current evidence points to a temporary workaround, not a permanent Part D decision. Permanent expansion would likely be costly, politically sensitive, and potentially require a more formal process than CMS is likely to complete before year-end. Given the short remaining window, the burden is on showing a concrete CMS rulemaking or announcement, and the provided sources do not yet confirm that such a step is imminent.

Relative to the current market price, my estimate is slightly higher than the market’s 11% Yes price, so I think the market is a bit too bearish. The market may be overweighting the fact that the bridge is not itself Part D coverage and underweighting the possibility that CMS uses late-2026 guidance to announce a more durable framework. Still, this remains a low-probability event because temporary access and permanent Part D inclusion are very different policy moves.